Catalyst Pharmaceuticals Inc (CPRX) - Total Liabilities
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has total liabilities worth $134.91 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Catalyst Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Catalyst Pharmaceuticals Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Catalyst Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Catalyst Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indorama Ventures PCL
BK:IVL
|
Thailand | ฿394.53 Billion |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
China | CN¥20.54 Billion |
|
Fujian Anjoy Foods Co Ltd
SHG:603345
|
China | CN¥4.09 Billion |
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
USA | $271.70 Million |
|
flatexDEGIRO AG
XETRA:FTK
|
Germany | €6.54 Billion |
|
LivaNova PLC
NASDAQ:LIVN
|
USA | $1.30 Billion |
|
AMP Ltd
AU:AMP
|
Australia | AU$30.47 Billion |
|
IONOS GROUP N
XETRA:IOS
|
Germany | €1.38 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Catalyst Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CPRX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Catalyst Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Catalyst Pharmaceuticals Inc (2002–2025)
The table below shows the annual total liabilities of Catalyst Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.54 Million | +23.24% |
| 2024-12-31 | $123.78 Million | +50.52% |
| 2023-12-31 | $82.23 Million | +9.34% |
| 2022-12-31 | $75.21 Million | +142.95% |
| 2021-12-31 | $30.96 Million | +36.04% |
| 2020-12-31 | $22.76 Million | -8.04% |
| 2019-12-31 | $24.75 Million | +156.01% |
| 2018-12-31 | $9.67 Million | +118.51% |
| 2017-12-31 | $4.42 Million | +84.48% |
| 2016-12-31 | $2.40 Million | -48.16% |
| 2015-12-31 | $4.63 Million | -46.63% |
| 2014-12-31 | $8.67 Million | +117.83% |
| 2013-12-31 | $3.98 Million | +83.57% |
| 2012-12-31 | $2.17 Million | -12.92% |
| 2011-12-31 | $2.49 Million | +693.27% |
| 2010-12-31 | $313.71K | -9.99% |
| 2009-12-31 | $348.52K | -76.34% |
| 2008-12-31 | $1.47 Million | +312.35% |
| 2007-12-31 | $357.17K | -53.79% |
| 2006-12-31 | $772.85K | +125.33% |
| 2005-12-31 | $342.99K | +405.88% |
| 2004-12-31 | $67.80K | +1.65% |
| 2002-12-31 | $66.70K | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more